CGAS and neoplasm: These functions of the protein-based cGAS-STING nanoagonist in the present study could act in a cooperative manner to enhance the DC-mediated cross-priming of antitumor effector T cells in TME and improve antitumor immune responses in poorly immunogenic tumor models, which provides emerging opportunities for enhancing the efficacy of immunotherapies against solid tumor indications in the clinics.